Passion and purpose to transform patient journeys in anxiety and depression.

Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i³ Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental roles in the successful commercial launch and sales of multiple CNS brands, including notably Lilly’s blockbuster CNS product, Cymbalta, for which she led the development and execution of the “Depression Hurts” consumer campaign, and a key Otsuka America CNS product, Rexulti, serving as Senior Director, Global Brand Lead. While at Lilly, she also led psychiatry sales teams as Area Sales Director responsible for Cymbalta, Zyprexa and Strattera. More recently, Ann led commercial development of a portfolio of products as Vice President, Neurodegenerative Disease and Psychiatry at Teva Pharmaceutical Industries. Ms. Cunningham holds a B.A. in Psychology from Yale University and an M.B.A. from the University of Michigan, Stephen M. Ross School of Business.